<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603951</url>
  </required_header>
  <id_info>
    <org_study_id>SHR2554-I-101</org_study_id>
    <nct_id>NCT03603951</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms</brief_title>
  <official_title>A Phase 1 Study to Characterize Safety, Tolerance, Pharmacokinetics and Efficacy of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 multicenter, single-arm, open-label, dose escalation and dose expansion&#xD;
      study of enhancer of zeste homolog 2 (EZH2 ) inhibitor SHR2554. This study is to assess the&#xD;
      tolerability, safety, pharmacokinetics, and preliminary anti-tumor activity of SHR2554 in&#xD;
      participants with relapsed or refractory mature lymphoid neoplasms.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 14, 2018</start_date>
  <completion_date type="Anticipated">June 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of treatment-emergent adverse events (AEs) [Safety and Tolerability])</measure>
    <time_frame>through study completion, an average of about 6 months</time_frame>
    <description>The incidence and severity of treatment-emergent AEs will be collected and the safety and tolerability of SHR2554 will be assessed.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase 2 dose (RP2D)</measure>
    <time_frame>30 days since the date of first dose</time_frame>
    <description>Recommended phase 2 dose (RP2D) and/or maximum tolerated dose (MTD) will be established according to the incidence of dose-limiting toxicities (DLTs) of escalated doses of SHR2554.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to peak (Tmax)</measure>
    <time_frame>Day 1 and Day 2 of the single dose</time_frame>
    <description>Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): Time to peak (Tmax) of plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Day 1 and Day 2 of the single dose</time_frame>
    <description>Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): Maximum plasma concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Halflife (T1/2)</measure>
    <time_frame>Day 1 and Day 2 of the single dose</time_frame>
    <description>Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): Halflife (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance/ bioavailability (CL/F)</measure>
    <time_frame>Day 1 and Day 2 of the single dose</time_frame>
    <description>Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): Clearance/ bioavailability (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparent volume of distribution/bioavailability (Vd/F)</measure>
    <time_frame>Day 1 and Day 2 of the single dose</time_frame>
    <description>Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): apparent volume of distribution/bioavailability (Vd/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve (AUC)</measure>
    <time_frame>Day 1 and Day 2 of the single dose</time_frame>
    <description>Pharmacokinetics profile of a single dose SHR2554 and its metabolite (plasma): Area under curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under curve, steady state (AUCss)</measure>
    <time_frame>Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)</time_frame>
    <description>Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Area under curve, steady state (AUCss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration, steady state (Cmax,ss)</measure>
    <time_frame>Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)</time_frame>
    <description>Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Maximum plasma concentration, steady state (Cmax,ss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to peak, steady state (Tmax,ss)</measure>
    <time_frame>Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)</time_frame>
    <description>Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Time to peak, steady state (Tmax,ss)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Halflife (T1/2)</measure>
    <time_frame>Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)</time_frame>
    <description>Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Halflife (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution, steady state/bioavailability (Vss/F)</measure>
    <time_frame>Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)</time_frame>
    <description>Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Apparent volume of distribution, steady state/bioavailability (Vss/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance/ bioavailability (CL/F)</measure>
    <time_frame>Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)</time_frame>
    <description>Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Clearance/ bioavailability (CL/F)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index (Rac)</measure>
    <time_frame>Day 1 of cycle 1 to day 1 of cycle 4 (28 days/cycle)</time_frame>
    <description>Pharmacokinetics profile of continuous medication of SHR2554 and its metabolite (plasma): Accumulation index (Rac)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>every 8 weeks through study completion, an average of about 6 months</time_frame>
    <description>Assess the response rate of subjects to the treatment of SHR2554</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>every 8 weeks through study completion, an average of about 6 months</time_frame>
    <description>Assess the survival condition of the subjects after the treatment of SHR2554</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>every 8 weeks through study completion, an average of about 6 months</time_frame>
    <description>Assess the duration of complete/partial response after the treatment of SHR2554</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of escalated doses of SHR2554 on the histone H3 lysine 27 trimethylation (H3K27me3) level</measure>
    <time_frame>day 1 of the single dose to day 1 of continuous medication cycle 2</time_frame>
    <description>Analyze the level of H3K27me3 in the peripheral blood mononuclear cells of the subjects before and after the treatment of escalated doses of SHR2554.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EZH2 gene mutation</measure>
    <time_frame>within 2 weeks after the last dose</time_frame>
    <description>Assess the known mutation of EZH2 gene in tumor cells or tissues, analyze the relationship between efficacy and EZH2 mutation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EZH2 expression level</measure>
    <time_frame>within 2 weeks after the last dose</time_frame>
    <description>Assess EZH2 expression level in tumor tissues, analyze the relationship between efficacy and EZH2 expression level</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Relapsed or Refractory Mature Lymphoid Neoplasms</condition>
  <arm_group>
    <arm_group_label>SHR2554 treated group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treated with escalated doses of EZH2 inhibitor SHR2554 respectively</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR2554</intervention_name>
    <description>SHR2554 is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2.</description>
    <arm_group_label>SHR2554 treated group</arm_group_label>
    <other_name>EZH2 Inhibitor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 to 70 years old (Adult, Senior)&#xD;
&#xD;
          2. Histologically or cytologically confirmed Mature lymphoid neoplasms&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1；&#xD;
&#xD;
          4. Has a life expectancy of ≥12 weeks；&#xD;
&#xD;
          5. Resistant to standard therapy or no standard therapy available，have indications for&#xD;
             treatment；&#xD;
&#xD;
          6. Have measurable disease （lymphoma participants，any nodes/nodal masses&gt;1.5 cm in&#xD;
             longest diameter (LDi) or extralymphatic sites of disease &gt;1.0 cm in LDi；Multiple&#xD;
             myeloma (MM) or Waldenström macroglobulinemia (WM) participants，serum M protein ≥0.5&#xD;
             g/dL or Bence Jones protein≥0.2 g/24 h）. （dose expansion study must satisfy）&#xD;
&#xD;
          7. Has sufficient tumor tissue (slides or blocks) available for testing EZH2 mutation&#xD;
             status and expression level. （dose expansion study must satisfy）&#xD;
&#xD;
          8. Diffuse large B-cell lymphoma (DLBCL) participants have immunohistochemistry test&#xD;
             results of cell origin (germinal center B-cell-like (GCB) or non-GCB), as well as&#xD;
             myelocytomatosis oncogene (MYC), B cell lymphoma/leukemia 2 (BCL2) and B-cell lymphoma&#xD;
             6 (BCL6), or provide sufficient tumor tissue for testing. （dose expansion study must&#xD;
             satisfy）&#xD;
&#xD;
          9. With adequate bone marrow function;&#xD;
&#xD;
         10. With adequate renal and liver function;&#xD;
&#xD;
         11. Coagulation function index：PT ≤1.5×ULN，APTT ≤1.5×ULN；&#xD;
&#xD;
         12. Women of childbearing potential (WOCBP) should be proven to be negative by human&#xD;
             chorionic gonadotropin (hCG) test in 7 days before the first dose of SHR2554. They&#xD;
             must be willing and able to employ a highly effective method of birth&#xD;
             control/contraception to prevent pregnancy from the day they sign the informed consent&#xD;
             form (ICF) to at least 30 days after receiving the last dose of study treatment. Male&#xD;
             subjects with WOCBP partner should receive Surgical sterilization or consent to employ&#xD;
             a highly effective method of birth control/contraception to prevent pregnancy；&#xD;
&#xD;
         13. Any prior treatment-related clinically significant toxicities have resolved to ≤ Grade&#xD;
             1 per CTCAE version 4.03 or prior treatment-related toxicities evaluated by physicians&#xD;
             are not clinically significant at time of enrollment.&#xD;
&#xD;
         14. Participant who has provided written consent to participate in the study and ability&#xD;
             to comply with all aspects of the protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior exposure to other inhibitor(s) of EZH2.&#xD;
&#xD;
          2. Participants with a presence of central nerves invasion&#xD;
&#xD;
          3. Auto-transplantation within 60 days or allo-transplantation within 90 days before the&#xD;
             first dose of study drug； &gt;1 grade graft-versus-host disease (GVHD) or using GVHD&#xD;
             control medicines that are not allowed by this trial；&#xD;
&#xD;
          4. Major surgery or serious trauma within 4 weeks before the first dose of study drug.；&#xD;
&#xD;
          5. anti-tumor agents within 4 weeks before the first dose of study drug（such as&#xD;
             chemotherapy, radiotherapy, immunotherapy, target therapy and other clinical&#xD;
             research）；Use of Chinese Herbal within 2 weeks before the first dose of study drug；use&#xD;
             of Glucocorticoids to anti tumor within 7 days before the first dose of study&#xD;
             drug（equivalent to prednisone&gt;20 mg/d）；&#xD;
&#xD;
          6. Has known active infection with hepatitis B virus or hepatitis C virus（HBV DNA≥2×10^3&#xD;
             IU/mL，HCV RNA≥10^3 IU/mL）and liver dysfunction，need the intervention of anti-virus&#xD;
             therapy;&#xD;
&#xD;
          7. Immunocompromised (i.e. has congenital immunodeficiency), including subjects known&#xD;
             history of infection with human immunodeficiency virus (HIV) or has known active&#xD;
             infection with tubercle bacillus；&#xD;
&#xD;
          8. Has an active infection or has a temperature &gt; 38.5°C with unknown&#xD;
             reasons（Investigators will decide the enrollment of participants with a fever that&#xD;
             contributed to tumors）；&#xD;
&#xD;
          9. Has cardiovascular impairment，including history of congestive heart failure greater&#xD;
             than New York Heart Association (NYHA) Class II, unstable angina, myocardial&#xD;
             infarction, or stroke within 1 year prior to the planned first dose of study drug; or&#xD;
             ventricular cardiac arrhythmia requiring medical treatment；&#xD;
&#xD;
         10. abnormal of ECG with clinical significance：such as prolongation of corrected QT&#xD;
             interval using Fridericia's formula (QTcF)(male &gt; 450 ms、female&gt; 470 ms）；&#xD;
&#xD;
         11. History of cerebrovascular accident or transient ischemic attack within 6 months；&#xD;
&#xD;
         12. Has a prior malignancy other than the malignancies under study within 2 years-&#xD;
             EXCEPTION: A subject with a history of a completely resected skin basal cell&#xD;
             carcinoma, skin squamous-celled carcinoma, in situ cervical cancer or other in situ&#xD;
             carcinomas, and has been relapse-free for 5 years；&#xD;
&#xD;
         13. Has serious acute/chronic disease or psychic disease，such as suicide intention or&#xD;
             action in resent 1 year; or there are abnormal conditions that will increase the risk&#xD;
             of using or managing study drug or affect the assessment of study results or&#xD;
             investigator's judgment；&#xD;
&#xD;
         14. Staffs of institute sites directly related to the study or their family members,&#xD;
             subordinates. Staffs of the sponsor pharmaceuticals company that directly related to&#xD;
             the study；&#xD;
&#xD;
         15. Females who are pregnant or breastfeeding.&#xD;
&#xD;
         16. Inability to take oral medication, or any uncontrolled gastrointestinal condition&#xD;
             (e.g., active gastroenteritis, chronic diarrhea, known diverticulosis, history of&#xD;
             gastrectomy or gastric banding) that might impair the bioavailability of study drug.&#xD;
             gastroesophageal reflux disease treated with proton pump inhibitors is eligible（should&#xD;
             be no drug interaction）;&#xD;
&#xD;
         17. Use of known median or potent CYP3A4 or CYP3A5 inducers/inhibitors or P-gp inhibitors.&#xD;
&#xD;
         18. Any other major illness that, in the investigator's judgment, will substantially&#xD;
             increase the risk associated with the subject's participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu Yao, MD</last_name>
    <phone>+86-021-68868570</phone>
    <email>yaoyu@hrglobe.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital, Peking University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>July 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SHR2554</keyword>
  <keyword>EZH2 inhibitor</keyword>
  <keyword>phase 1</keyword>
  <keyword>mature lymphoid neoplasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

